Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Two jailed for forcing disabled teens into prostitution
-
3
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
4
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
5
S. Korea not to attend Sado mine memorial: foreign ministry
-
6
South Korean military plans to launch new division for future warfare
-
7
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
8
North Korean leader ‘convinced’ dialogue won’t change US hostility
-
9
Hyundai Motor’s Genesis US push challenged by Trump’s tariff hike: sources
-
10
Toxins at 622 times legal limit found in kids' clothes from Chinese platforms
[Newsmaker] ABL Bio begins clinical trial of anticancer drug candidate
By Shim Woo-hyunPublished : Oct. 7, 2021 - 17:20
South Korean biotech firm ABL Bio said Thursday that it has begun the phase 1 clinical trial of anticancer drug candidate ABL501.
ABL501 is an antibody that uses the Grabody-I platform technology to block both the PD-L1 and LAG-3 checkpoint pathways, improving the current limitation in PD-L1 therapies.
ABL Bio said the company has administered the drug candidate to the first patient with a solid tumor at Samsung Medical Center in Seoul.
An official from ABL Bio said the phase 1 clinical trial started earlier than planned. The company expects to accelerate development of the drug candidate, the official added.
The biotech company’s phase 1 clinical study involves a total of 36 patients with advanced or metastatic solid tumors at Samsung Medical Center, Seoul National University Hospital, Asan Medical Center and Severance Hospital.
The phase 1 clinical study will test safety, tolerability, preliminary efficacy and maximum tolerated dose in patients, according to the company.
In August, ABL Bio’s Investigational New Drug application for ABL501 was approved by South Korea‘s Ministry of Food and Drug Safety.
The company plans to commence a clinical trial of ABL501 in China by the end of this year, together with its partner firm I-Mab Biopharma.
ABL501 is an antibody that uses the Grabody-I platform technology to block both the PD-L1 and LAG-3 checkpoint pathways, improving the current limitation in PD-L1 therapies.
ABL Bio said the company has administered the drug candidate to the first patient with a solid tumor at Samsung Medical Center in Seoul.
An official from ABL Bio said the phase 1 clinical trial started earlier than planned. The company expects to accelerate development of the drug candidate, the official added.
The biotech company’s phase 1 clinical study involves a total of 36 patients with advanced or metastatic solid tumors at Samsung Medical Center, Seoul National University Hospital, Asan Medical Center and Severance Hospital.
The phase 1 clinical study will test safety, tolerability, preliminary efficacy and maximum tolerated dose in patients, according to the company.
In August, ABL Bio’s Investigational New Drug application for ABL501 was approved by South Korea‘s Ministry of Food and Drug Safety.
The company plans to commence a clinical trial of ABL501 in China by the end of this year, together with its partner firm I-Mab Biopharma.
